Roche announced the results of the first phase-III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy (FOLFOX) for the treatment of colon cancer immediately following surgery (adjuvant therapy) compared to chemotherapy alone. The study, known as NSABP C-08, did not meet its primary endpoint of lowering the risk of the cancer returning (disease-free survival). This is the first trial of Avastin in early-stage cancer and results do not affect approved indications in advanced (metastatic) disease.
The details can be read here.
1 comment:
I think the Avastin is a big bubble should be finished for example :
1. CRC with Oxaliplatin was not impressive.
2. Breast cancer with old product called Paclitaxel was given a good result but in the other hand with the newest & most common drug Docetaxel with a trial called Avado trial ; it seems the result was not so impressive they tried to promoted the Hazard ratio rather than a clinical result.
3. Lung cancer : at the beginning with Paclitaxel it was made a good survival a trial called E4599 by A Sandler published at 2006 at NEJM it is add 2 months for overall survival (from 10.2 to 12.2 ) with a double dose and of course a double cost
4. Renal cell carcinoma : same story; without any advantages regarding survival
Kindly note the British health system was refused Avastin for CRC due to lack cost effectiveness
Is it worth this!!!
Post a Comment